← The feed Many Minded · The brief
HEALTH · forward · impact 2/5 · 2026-11-18

One German patient's three autoimmune diseases go quiet after CAR-T infusion

A 47-year-old woman in Germany reached complete remission after one anti-CD19 CAR-T infusion. It is a single case with about 11 months of follow-up.

A 47-year-old woman in Germany, ill for more than ten years with three autoimmune diseases, reached complete remission after a single infusion of anti-CD19 CAR-T cells. Her main diagnosis was autoimmune hemolytic anemia, alongside antiphospholipid antibody syndrome and immune thrombocytopenia. Before treatment she needed daily blood transfusions and regular blood-thinning drugs, and nine earlier treatments had not worked for long. The case report was published in the journal Med in 2026, with Fabian Müller of University Hospital Erlangen as lead clinician.

Researchers took her T cells, engineered them to target CD19, a protein on the surface of B cells, and infused them back. She stopped needing transfusions seven days later and went home at day 10. By day 25 biomarkers showed complete remission: hemoglobin normalized, platelet counts stabilized, and the clot-triggering antibodies could no longer be detected. B cells began returning after 322 days, almost all of them naive. Around then she stopped her anticlotting drugs and had no new clots. She had no cytokine release syndrome or nerve toxicity. Mildly raised liver enzymes and a platelet dip were possibly lingering effects of earlier treatments.

The significance for abundance is the shape of the treatment. Instead of daily transfusions and lifelong drugs, this is one infusion that resets the immune system. If it holds up, a one-time procedure could replace continuing care that consumes clinic time, blood supply and money. A January study reported that 11 patients with treatment-resistant autoimmune hemolytic anemia reached complete remission after one CAR-T infusion. Two relapsed within about eight months and responded to a second, differently targeted therapy.

The caution is large. This is one patient with about 11 months of follow-up. Independent hematologist Cristina Pascual Izquierdo called it a highly suggestive preliminary signal, not definitive evidence. One case cannot show the therapy will work for every patient. Larger trials and longer follow-up are what to watch.

Source: ScienceAlert